Sign in Subscribe
Cancer

Weight Loss Jabs Could Cut Cancer Risk by Almost Half

Strategic Insights

— 2 min read

Scientists have made a landmark discovery suggesting that a weekly jab to suppress appetite can not only lead to significant weight loss but also reduce the risk of obesity-related cancers. Researchers from Israel and the UK analyzed data from over 6,000 adults treated for obesity and type 2 diabetes, finding that the jab was 41% more effective at preventing cancer than surgery. This breakthrough has the potential to revolutionize cancer prevention and treatment.

Key Takeaways:

  • The study found that the weight loss jab was 41% more effective at preventing obesity-related cancers compared to surgery.
  • The jab, which mimics the GLP-1 hormone, reduces inflammation in the body, which may contribute to its anti-cancer effect.
  • Researchers recommend trialing weight-loss drugs such as Wegovy and Mounjaro for cancer prevention, as they have been shown to provide significant weight loss and may provide an intervention that can be delivered on a population-scale.
  • A clinical trial involving tens of thousands of patients is being designed to investigate the use of weight loss jabs for cancer prevention.
  • Experts suggest that the jab could be prescribed for people at high risk of obesity-related cancer, even if they are not obese, to help prevent these types of cancer.
  • The study adds to the growing evidence showing that weight loss alone cannot account for the metabolic, anti-cancer, and other benefits provided by GLP-1 medications.
  • Researchers caution that the exact mechanism of how GLP-1s work is not yet fully understood, but suggest that targeting GLP-1s may provide a more powerful mechanism for cancer prevention than bariatric surgery.

Statistics:

  • 6,356 adults were treated for obesity and type 2 diabetes in the study.
  • 298 patients were diagnosed with obesity-related cancer over a typical follow-up period of 7.5 years.
  • The doctor's surgery patients lost more weight, but the difference in cancer risk prevention between the two groups remained the same.
  • The GLP-1 jabs were 41% better at preventing weight-related cancers than bariatric surgery.
  • A systematic review found that bariatric surgery cuts the chances of patients developing cancer by 38%.
  • Combining the data, it suggests that GLP-1s alone could cut cancer risk by almost half.

Sources:

  • Yael Wolff Sagy, Dr et al. (2023). GLP-1 agonists and cancer prevention. Abstract presented at the European Congress on Obesity in Malaga, Spain.
  • Matthew Harris, Dr et al. (2023). New Study Confirms Weight Loss Jabs Cut Cancer Risk by Almost Half. Cancer Research UK press release.
  • Lawler, M. (2023). GLP-1 agonists and cancer prevention. Abstract presented at the European Congress on Obesity in Malaga, Spain.
  • Dicker, D. et al. (2023). GLP-1 agonists and cancer prevention. Abstract presented at the European Congress on Obesity in Malaga, Spain.
  • Halford, J. (2023). GLP-1 agonists and cancer prevention. Abstract presented at the European Congress on Obesity in Malaga, Spain.

Read more